These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15902588)

  • 21. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

  • 22. [Fluvoxamine and serotonin syndrome in a patient with Parkinson disease].
    Le Cavorzin P; Sarkis S; Bénéton C; Pinel JF; Maruelle L; Le Vaou P; Allain H
    Therapie; 1996; 51(2):195-6. PubMed ID: 8763057
    [No Abstract]   [Full Text] [Related]  

  • 23. Serotonin syndrome induced by fluvoxamine-lithium interaction.
    Ohman R; Spigset O
    Pharmacopsychiatry; 1993 Nov; 26(6):263-4. PubMed ID: 8127934
    [No Abstract]   [Full Text] [Related]  

  • 24. High CSF Tau-protein concentration in delirium induced by high dose psychiatric medication.
    Windhagen A; Wurster U; Kropp S; Ziegenbein M
    Aust N Z J Psychiatry; 2006; 40(11-12):1039-41. PubMed ID: 17054574
    [No Abstract]   [Full Text] [Related]  

  • 25. Fluvoxamine-associated oscillopsia and a role for personalized medication dosing.
    Singman EL; Hocum B; Yohannan J; Pearson V
    Drug Metab Pers Ther; 2015 Dec; 30(4):271-5. PubMed ID: 26351962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbamazepine and/or fluvoxamine drug interaction with risperidone in a patient on multiple psychotropic medications.
    Alfaro CL; Nicolson R; Lenane M; Rapoport JL
    Ann Pharmacother; 2000 Jan; 34(1):122-3. PubMed ID: 10669197
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression.
    Oswald P; Souery D; Mendlewicz J
    Int J Neuropsychopharmacol; 2003 Mar; 6(1):85-7. PubMed ID: 12899739
    [No Abstract]   [Full Text] [Related]  

  • 28. Hair loss associated with fluvoxamine use.
    Parameshwar E
    Am J Psychiatry; 1996 Apr; 153(4):581-2. PubMed ID: 8599419
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics.
    Spigset O; Ohman R
    J Clin Psychopharmacol; 1996 Jun; 16(3):254-5. PubMed ID: 8784660
    [No Abstract]   [Full Text] [Related]  

  • 30. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of adolescent body dysmorphic disorder treated with fluvoxamine.
    Khan S; Decker D
    J Child Adolesc Psychopharmacol; 2001; 11(1):105-7. PubMed ID: 11322739
    [No Abstract]   [Full Text] [Related]  

  • 33. Lithium and venlafaxine interaction: a case of serotonin syndrome.
    Adan-Manes J; Novalbos J; López-Rodríguez R; Ayuso-Mateos JL; Abad-Santos F
    J Clin Pharm Ther; 2006 Aug; 31(4):397-400. PubMed ID: 16882112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful electroconvulsive therapy in major depression with fluvoxamine-induced bruxism.
    Miyaoka T; Yasukawa R; Mihara T; Shimizu Y; Tsubouchi K; Maeda T; Mizuno S; Uegaki J; Inagaki T; Horiguchi J; Tachibana H
    J ECT; 2003 Sep; 19(3):170-2. PubMed ID: 12972988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
    Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment.
    Mauri MC; Ferrara A; Boscati L; Bravin S; Zamberlan F; Alecci M; Invernizzi G
    Neuropsychobiology; 1998; 37(3):124-9. PubMed ID: 9597668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder.
    Park YM; Lee HJ; Kang SG; Choo CS; Cho JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):380-1. PubMed ID: 19121360
    [No Abstract]   [Full Text] [Related]  

  • 39. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].
    Buhagiar K; Cassar J
    Turk Psikiyatri Derg; 2007; 18(2):179-83. PubMed ID: 17566884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should adjunctive antipsychotic treatment be continued in remitted patients with depression?
    Uchida H; Suzuki T; Watanabe K; Kashima H
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):126. PubMed ID: 19154222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.